MEPERGAN
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Nov 1961
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MEPERGAN is an injectable combination product approved in 1961 by Hikma, representing a legacy formulation in the injectable pharmaceutical market. The specific mechanism of action and therapeutic indications are not publicly disclosed in available data. This product operates as a traditional small molecule injectable with a well-established safety and manufacturing history.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), indicating a contracting commercial organization and transitional career opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on MEPERGAN represents a career opportunity in lifecycle management and defensive marketing as the product approaches loss of exclusivity. Positions emphasize operational excellence, cost optimization, and market transition planning rather than growth or innovation.
Brand ManagerMedical Science Liaison
Worked on MEPERGAN at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.